ALFA Finder| Revenue growth | 32% YoY growth in FY26 to ₹998.8cr. |
|---|---|
| Margins | EBITDA margins improved 100bps to 23.8%; PAT margins up 310bps. |
| Demand visibility | Strong; dialysis is non-discretionary with projected 13% CAGR market growth. |
| Management confidence | High; citing India platform's success in driving international growth. |
Growth
FY26 revenue up 32% to ₹998.8cr; Adjusted EBITDA grew 37% to ₹238.2cr; Adjusted PAT surged 74.6% to ₹128.3cr.
Outlook
Medium-term revenue CAGR guidance of 15-20%; plans to add 40-50 clinics in India and 10-15 in Philippines annually.
Risks
Regulatory complexities in international markets; potential non-renewal of PPP contracts like Uttarakhand; high working capital requirements.
Earnings Call filed with NSE, NSE: NEPHROPLUS. Summary written with AI assistance from the document.
Nephrocare Health Services Ltd: key numbers
- Share price
- ₹630.40
- Market cap
- ₹6,325 Cr
- Revenue (annual)
- ₹998.8 Cr
- Net profit (annual)
- ₹76.84 Cr
- P/E (TTM)
- 49.4×Sector 54.5×
- Promoter holding
- 58.31%-5.54% QoQ
- FII holding
- 11.73%Current quarter
Reference market data from a third-party provider, updated daily. Not a valuation or a recommendation.
More from Nephrocare Health Services Ltd
All →Nephrocare Health Services Earnings Call Transcript: Key Takeaways
Revenue grew a healthy 23.5%, but adjusted EBITDA lagged and H1 margin fell about 80bps to 23%. Management deflected on pricing, FX and margin detail, relying on 'healthy range' language and long-term guidance.
Nephrocare Health Services Other Announcement
Nephrocare filed Crisil's monitoring agency report on IPO proceeds for the quarter ended 30 September 2026. The report shows no deviation from the stated objects.
Nephrocare Health Services Investor Presentation: Key Takeaways
H1FY27 revenue ₹585.2 Cr (+23.6% YoY), Adj EBITDA ₹134.4 Cr (+15.3%), Adj PAT ₹76.1 Cr (+34.7%). Expansion via acquisitions in Philippines, Kazakhstan and Saudi Arabia.
Nephrocare Health Services Results Update
Nephrocare Health Services released its Q2 and H1 FY27 results press release. Revenue and adjusted profit grew year-on-year, alongside network expansion into Kazakhstan.
Nephrocare Health Services Q2 FY27 Results: Turns Profitable, Net Profit ₹33.5 Cr
Nephrocare Health Services Ltd reported revenue from operations of ₹303.4 Cr (+23.5% YoY) and net profit of ₹33.5 Cr for Q2 FY27.
- Key figure
- Net profit ₹33.5 Cr
Nephrocare Health Services Legal & Regulatory
Nephrocare's Uzbek subsidiary won a court ruling invalidating a ₹14.79 crore tax demand. The tax department must reconsider the audit, and the decision remains appealable.
- Value
- ₹14.79 Cr